Data points from yesterday that brings confidence Itsa:
The European 2B trial will only be 12 months - great outcome....not protracted multi-year.
Trial efficacy end points accepted by agencies - Pul2 & Myoset (same as Aussie P2)
Agencies say positive results from Euro trial above paves way forward for EMA drug approval.
FDA discussion now back on agenda - maybe ANP will be white knight for Sarepta's FDA issues re Exondys51.
No CR until mid 2020 - awesome, means funding from elsewhere (Oppies,Partnerships?)
Sarepta net quarterly revenue US$95m from 13% of market AU$500m annually.
Sarepta need to satisfy FDA efficacy requests pronto!
New IP / clinical studies for new indications targeting CD49d.
My thoughts: if any BigPharma is looking on with interest, surely they will move before Phase 2b is complete, otherwise they will be paying premium $$$ by that point if 2B is successful.
Phase 2 is the "sweet spot" for Biotech M&A.
Pipe-dream maybe. But very probable given Sarepta's predicament.
.
- Forums
- ASX - By Stock
- PER
- Ann: AGM Presentation 2019
Ann: AGM Presentation 2019, page-65
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $66.26M |
Open | High | Low | Value | Volume |
7.4¢ | 7.4¢ | 7.0¢ | $40.71K | 565.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 69746 | 7.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.2¢ | 18053 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 69746 | 0.070 |
3 | 143090 | 0.069 |
3 | 33055 | 0.068 |
2 | 109310 | 0.067 |
2 | 15360 | 0.066 |
Price($) | Vol. | No. |
---|---|---|
0.072 | 18053 | 1 |
0.073 | 35755 | 1 |
0.075 | 63371 | 2 |
0.078 | 75476 | 2 |
0.079 | 175123 | 2 |
Last trade - 12.59pm 31/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online